Lamellar Biomedical says lung treatment could save lives of Covid-19 patients

Lanarkshire firm Lamellar Biomedical says one of its treatments could help save lives by halting progression of lung damage in Covid-19 patients.

The company has pre-clinical evidence that Lamellasome can protect lung cells and tissue if inhaled within five to eight days of symptoms of respiratory lung disease.

It says early intervention can prevent the Acute Respiratory Distress Syndrome (ARDS) seen in coronavirus patients.

Investors include Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and it works in partnership with the universities of Edinburgh and Strathclyde.

Read more HERE.